Bioo Scientific Launches Kit for Targeted siRNA Delivery Into Any Cell Type
Bioo Scientific announced the launch of their T3™ Conjugation Kit, which allows scientists to deliver siRNA into targeted cell types.
Austin, TX, December 12, 2009 --(PR.com)-- Bioo Scientific has introduced the patent pending T3™ Conjugation Kit for targeted in vivo delivery of siRNA or any other RNAi agent. The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cells or cell lines, which have mixed cell populations. Bioo Scientific has built upon its expertise in RNAi delivery to create a technology that will offer customers the ability to effectively delivery siRNA or microRNA (miRNA) into any targeted cell or tissue type they are studying.
RNAi has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. However, achieving efficient in vivo delivery of siRNA to the appropriate target cell has been a major hurdle in the advancement of using RNAi in gene function studies and as a therapeutic agent. This hurdle can now be easily overcome using the T3 Conjugation Kit.
The T3 technology functions by conjugating a T3 Carrier to an antibody that is specific to a receptor or other extracellular domain specific to the targeted cell or tissue type. The T3 Carrier-Antibody Conjugate can then be loaded with an RNAi agent such as siRNA or miRNA. The RNAi agent loaded T3 Conjugate may then be administered systemically or locally to an animal (or cultured cells) where it binds to and is internalized by cells recognized by the antibody. Once inside the cell, the RNAi agent is designed for release from T3 allowing silencing of its intended target. The T3 Conjugation Kit technology will propel the validation of in vivo work, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
According to Dr. Masoud Toloue, Senior Scientist at Bioo Scientific, “siRNA/miRNA delivery remains the largest hurdle for in vivo research application and all efforts to make RNAi a real therapeutic modality. With the launch of our T3 Conjugation Kit, both scientists and clinicians will have access to an antibody based siRNA/miRNA delivery vehicle that allows the user to choose any antibody and siRNA/miRNA combination for their research. For the first time, T3’s targeting technology enables users to concentrate RNAi mediator on their tissue/organ or tumor of focus while limiting systemic toxicity and significantly reducing current dose requirements. As the first commercial siRNA targeted delivery vehicle to market, T3 will advance and revolutionize the entire siRNA delivery arena.” This research was funded in part by grants from the National Science Foundation.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
###
RNAi has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. However, achieving efficient in vivo delivery of siRNA to the appropriate target cell has been a major hurdle in the advancement of using RNAi in gene function studies and as a therapeutic agent. This hurdle can now be easily overcome using the T3 Conjugation Kit.
The T3 technology functions by conjugating a T3 Carrier to an antibody that is specific to a receptor or other extracellular domain specific to the targeted cell or tissue type. The T3 Carrier-Antibody Conjugate can then be loaded with an RNAi agent such as siRNA or miRNA. The RNAi agent loaded T3 Conjugate may then be administered systemically or locally to an animal (or cultured cells) where it binds to and is internalized by cells recognized by the antibody. Once inside the cell, the RNAi agent is designed for release from T3 allowing silencing of its intended target. The T3 Conjugation Kit technology will propel the validation of in vivo work, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
According to Dr. Masoud Toloue, Senior Scientist at Bioo Scientific, “siRNA/miRNA delivery remains the largest hurdle for in vivo research application and all efforts to make RNAi a real therapeutic modality. With the launch of our T3 Conjugation Kit, both scientists and clinicians will have access to an antibody based siRNA/miRNA delivery vehicle that allows the user to choose any antibody and siRNA/miRNA combination for their research. For the first time, T3’s targeting technology enables users to concentrate RNAi mediator on their tissue/organ or tumor of focus while limiting systemic toxicity and significantly reducing current dose requirements. As the first commercial siRNA targeted delivery vehicle to market, T3 will advance and revolutionize the entire siRNA delivery arena.” This research was funded in part by grants from the National Science Foundation.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
###
Contact
Bioo Scientific
Dawn Obermoeller
512-707-8993
http://www.biooscientific.com
Dawn Obermoeller
512-707-8993
http://www.biooscientific.com
Contact
Categories